News
1d
Zacks Investment Research on MSNFDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV PillMerck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...
Over the past three decades, there have been amazing advances in treating and preventing HIV. Subscribe to our newsletter for ...
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...
Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...
This new FDA-approved shot is designed to break down the barriers that have kept too many people from accessing PrEP.
The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...
As more people live longer with HIV, Thomas Street at Quentin Mease Health Center is expanding services to address the ...
Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...
Discover how understanding your viral load and CD4 count puts you in control of HIV treatment and transforms confusing ...
17don MSNOpinion
Elton John and Jeanine White, the mother of Ryan White, urge Congress not to cut funding for lifesaving HIV and AIDS programs ...
While many big drug companies do amazing things for humanity, they’re also often vilified for profiteering from their work. This month, New York-listed Gilead Sciences has, not for the first time, ...
Jeremy Gregson was sitting in his Northwest Indiana home two years ago when he got the call that his blood work from earlier ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results